gene therapy
Biogen and Capsigen to collaborate on novel gene therapies
May 11, 2021Manufacturing and Production gene therapy
Biogen and Capsigen have announced a research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to …
Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy
March 25, 2020Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy
Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …
Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy
September 23, 2019Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma
Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …
NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy
September 4, 2019Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
EMA approves Bluebird Bio’s gene therapy Zynteglo
June 4, 2019Manufacturing and Production Bluebird Bio, European comission, gene therapy, health, pharma
The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo. The Massachusetts-based firm’s one time …
Doctors cure ‘bubble boy syndrome’ using modified version of HIV
April 18, 2019Research and Development HIV, SCID-X1, gene therapy, immunodeficiency, immunology
Doctors at St. Jude Children’s Research Hospital have been able to treat patients with X-linked severe combined immunodeficiency (SCID-X1) – …
CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia
April 1, 2019Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
Roche set to acquire Spark Therapeutics in $4.8 billion deal
February 25, 2019Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma
Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …
Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx
February 1, 2019Medical Communications, Research and Development, Sales and Marketing Janssen, MeiraGTx, eye care, gene therapy, pharma
In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage …
Scientists prevent axon self-destruct mechanism using gene therapy
January 17, 2019Research and Development Axon, gene therapy, health, neuropathy
Scientists at the University of Washington have developed a gene therapy that prevents the process through which axons (nerve fibres) …
US regulator to recruit 50 new gene and cell therapy clinical reviewers
January 16, 2019Research and Development FDA, cell therapy, gene therapy, regulation
FDA Commissioner Scott Gottlieb has said that the agency hopes to recruit 50 additional clinical reviewers for the group that …
Eli Lilly to buy Loxo Oncology in deal worth $8 billion
January 7, 2019Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine
US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …
Novartis cuts 20% of research projects
November 1, 2018Business Services, Research and Development Business, Novartis, gene therapy, infectious diseases, research
Swiss multinational Novartis has cut a fifth of its research projects, as it abandons 90 of its 430 drug development …
Astellas acquires gene therapy group Quethera in £85 million deal
August 13, 2018Sales and Marketing Astellas, Japan, gene therapy, ocular, quethera, vision
The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million. …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
